Abstract Background and Objectives: Pirfenidone is an orally available antifibrotic agent that
has shown benefit in animal models of pulmonary and renal fibrosis and in clinical trials of
pulmonary fibrosis, multiple sclerosis, and hepatic cirrhosis. Our objective was to determine
whether pirfenidone slows the loss of renal function in focal segmental glomerulosclerosis.
Design, Setting, Participants, & Measurements: An open-label trial was performed to
evaluate the safety and efficacy of pirfenidone in patients with idiopathic and postadaptive …